1.Association between Reproductive Factors and Cardiovascular Disease Risk in Post-Menopausal Women: Cross-Sectional Study from the 2016–2017 Korea National Health and Nutrition Examination Survey
Jiyoun KANG ; Jieun KIM ; Nanie YU ; Heecheol KANG
Korean Journal of Family Practice 2020;10(3):182-191
Background:
Reproductive factors such as childbirth, gravidity, age of menarche, breastfeeding, and use of oral contraceptives could affect the risk of cardiovascular disease in women. This study aimed to investigate the relationship between reproductive factors and cardiovascular disease in postmenopausal women in Korea.
Methods:
This study included 2,310 women aged ≥45 years who experienced natural menopause and participated in the 7th Korea National Health and Nutrition Examination Survey (2016–2017). Cardiovascular disease was defined as myocardial infarction, angina, and stroke. Coronary heart disease was defined as myocardial infarction and angina. Logistic regression was performed to calculate the odds ratio of cardiovascular disease with respect to each reproductive factor.
Results:
Women who breastfed for longer duration (≥24 months) group had a 3-fold higher risk of cardiovascular disease and 4–5-fold higher risk of coronary heart disease than those in the non-breastfeeding group. One-time pregnancy was associated with a higher risk of coronary heart disease than gravidity of 6. Early menarche (≤11 years of age) was associated with a high risk of stroke. Women who had a history of using oral contraceptives were at low risk of stroke.
Conclusion
Breastfeeding, low gravidity, and early menarche were associated with an increased risk of cardiovascular disease, whereas use of oral contraceptives was associated with reduced risk of stroke. However, some of these results were different from previous reports. Therefore, further studies are needed to identify the relationship between reproductive factors and cardiovascular disease in women.
2.Epidemiology and Clinical Characteristics of Clostridium difficile Infection in a Korean Tertiary Hospital.
Jieun KIM ; Hyunjoo PAI ; Mi ran SEO ; Jung Oak KANG
Journal of Korean Medical Science 2011;26(10):1258-1264
In order to investigate the incidence, clinical and microbiologic characteristics of Clostridium difficile infection (CDI) in Korea, a prospective observational study was performed. From September 2008 through January 2010, all patients whose stool was tested for toxin assay A&B and/or C. difficile culture were studied for clinical characteristics. Toxin types of the isolates from stool were tested. The mean incidence of CDI per 100,000 patient-days was 71.6 by month (range, 52.5-114.0), and the ratio of CDI to antibiotic-associated diarrhea was 0.23. Among 200 CDI patients, 37.5% (75/200) was severe CDI based on severity score. Clinical outcome of 189 CDI was as followed; 25.9% (49/189) improved without treatment, 84.3% (118/140) achieved clinical cure and attributed mortality was 0.7% (1/140) with the treatment. Recurrence rate was 21.4% (30/140) and cure without recurrence was 66.4% (93/140). The most common type of toxin was toxin A-positive/toxin B-positive strain (77.5%), toxin A-negative/toxin B-positive strains or binary toxin-producing strains comprised 15.4% or 7.1%, respectively. In conclusion, the incidence of CDI in Korea is a little higher than other reports during the non-epidemic setting. We expect that the change of epidemiology and clinical severity in CDI can be evaluated based on these results.
Aged
;
Bacterial Proteins/analysis
;
Bacterial Toxins/analysis
;
Clostridium Infections/*epidemiology/physiopathology
;
Clostridium difficile/*isolation & purification/*pathogenicity
;
Diarrhea/epidemiology/microbiology
;
Enterocolitis, Pseudomembranous/*epidemiology/microbiology/pathology
;
Enterotoxins/analysis
;
Feces/microbiology
;
Female
;
Hospitals
;
Humans
;
Incidence
;
Male
;
Metronidazole/therapeutic use
;
Middle Aged
;
Prospective Studies
;
Recurrence
;
Republic of Korea/epidemiology
;
Treatment Outcome
;
Vancomycin/therapeutic use
3.An Approach to Survey Data with Nonresponse: Evaluation of KEPEC Data with BMI.
Jieun BAEK ; Weechang KANG ; Youngjo LEE ; Byung Joo PARK
Korean Journal of Preventive Medicine 2002;35(2):136-140
OBJECTIVES: A common problem with analyzing survey data involves incomplete data with either a nonresponse or missing data. The mail questionnaire survey conducted for collecting lifestyle variables on the members of the Korean Elderly Phamacoepidemiologic Cohort(KEPEC) in 1996 contains some nonresponse or missing data. The proper statistical method was applied to evaluate the missing pattern of a specific KEPEC data, which had no missing data in the independent variable and missing data in the response variable, BMI. METHODS: The number of study subjects was 8,689 elderly people. Initially, the BMI and significant variables that influenced the BMI were categorized. After fitting the log-linear model, the probabilities of the people on each category were estimated. The EM algorithm was implemented using a log-linear model to determine the missing mechanism causing the nonresponse. RESULTS: Age, smoking status, and a preference of spicy hot food were chosen as variables that influenced the BMI. As a result of fitting the nonignorable and ignorable nonresponse log-linear model considering these variables, the difference in the deviance in these two models was 0.0034(df=1). CONCLUSION: There is a lot of risk if an inference regarding the variables and large samples is made without considering the pattern of missing data. On the basis of these results, the missing data occurring in the BMI is the ignorable nonresponse. Therefore, when analyzing the BMI in KEPEC data, the inference can be made about the data without considering the missing data.
Aged
;
Body Mass Index
;
Humans
;
Life Style
;
Linear Models
;
Postal Service
;
Surveys and Questionnaires
;
Smoke
;
Smoking
5.Recent Epidemiological Changes in Group B Streptococcus Among Pregnant Korean Women
Seong Jin CHOI ; Jieun KANG ; Young UH
Annals of Laboratory Medicine 2021;41(4):380-385
Background:
Although group B Streptococcus (GBS) colonization rate among pregnant Korean women is lower than that among women from many Western countries, recent data show an upward trend. We investigated recent epidemiological changes in GBS among pregnant Korean women in terms of colonization rate, antimicrobial susceptibility, serotype, and resistance genotype.
Methods:
Vaginal and anorectal swab specimens from 379 pregnant Korean women were cultured on Strep B Carrot Broth with GBS Detect (Hardy Diagnostics, USA), selective Todd-Hewitt broth (Becton Dickinson, USA), and Granada agar plate medium (Becton Dickinson). The antimicrobial susceptibility, serotypes, and macrolide-lincosamide-streptogramin B (MLS B) resistance genes of the GBS isolates were tested.
Results:
The GBS colonization rate among pregnant Korean women was 19.8% (75/379).Colonization rates using Strep B Carrot Broth with GBS Detect, selective Todd-Hewitt broth, and Granada agar plate medium cultures were 19.5%, 19.3%, and 15.0%, respectively.Six pregnant women were colonized by non-beta-hemolytic GBS and were detected only in Strep B Carrot Broth with GBS Detect. Resistance rates of GBS to clindamycin, erythromycin, and tetracycline were 16.0%, 28.0%, and 42.7%, respectively. The most common GBS serotypes were V (22.7%), VIII (20.0%), and III (20.0%). The frequency of MLS B resistance genes erm(B) and erm(TR) were 63.6% and 36.4%, respectively.
Conclusions
The GBS colonization rate among pregnant Korean women has risen to levels observed in Western countries. To accurately evaluate GBS epidemiology among pregnant Korean women, periodic studies in multiple centers, including primary clinics, are necessary.
6.Regional disparities in the availability of cancer clinical trials in Korea
Jieun JANG ; Wonyoung CHOI ; Sung Hoon SIM ; Sokbom KANG
Epidemiology and Health 2024;46(1):e2024006-
OBJECTIVES:
Unequal access to cancer clinical trials is an important issue, given the potential benefits of participation for cancer patients. We evaluated regional disparities in access to cancer clinical trials in Korea.
METHODS:
From the Ministry of Food and Drug Safety database, we extracted 2,465 records of all cancer clinical trials approved between January 2012 and April 2023. To measure disparities in cancer clinical trial access, we calculated the ratio of clinical trials open to non-capital areas relative to those open to capital areas. We then analyzed temporal trends in this ratio, which we termed the trial geographical equity index (TGEI).
RESULTS:
Disparities in access to cancer clinical trials, as indicated by the TGEI, did not significantly improve during the study period (regression coefficient, 0.002; p=0.59). However, for phase II/III trials sponsored by global pharmaceutical companies, the TGEI improved significantly (regression coefficient, 0.021; p<0.01). In contrast, the TGEI deteriorated for trials initiated by investigators or those testing domestically developed therapeutics (regression coefficient, -0.015; p=0.05). Furthermore, the increasing trend of TGEI for phase II/III trials sponsored by global companies began to reverse after 2019, coinciding with the outbreak of coronavirus disease 2019 (COVID-19).
CONCLUSIONS
Over the past decade, access to cancer clinical trials has improved in Korea, particularly for phase II/III trials evaluating therapeutics from global companies. However, this increase in accessibility has not extended to trials initiated by investigators or those assessing domestically developed therapeutics. Additionally, the impact of COVID-19 on disparities in clinical trial access should be closely monitored.
7.Pyrazinamide-Induced Urticaria and Angioedema: a Case Report.
Yewon KANG ; Jieun KANG ; Kyoungmin LEE ; Dae Hyun JEONG ; Soomin NOH ; Bomi SEO ; Tae Bum KIM
Korean Journal of Medicine 2018;93(3):306-310
Pyrazinamide (PZA) is an anti-tuberculosis drug and an essential component of the standard four-drug regimen for tuberculosis. Here, we report a case of immediate angioedema secondary to PZA administration intended for pulmonary tuberculosis treatment. A previously healthy 48-year-old woman was diagnosed with pulmonary tuberculosis and tuberculous lymphadenitis. Thirty minutes after taking the first dose of isoniazid, rifampicin, pyrazinamide, and ethambutol, the patient developed facial edema, generalized rash, and dizziness. An oral provocation test was performed on the four drugs, and 1,000 mg pyrazinamide showed a positive result characterized by 50 minutes of urticaria, angioedema, and hypotension. As the prevalence of tuberculosis increases, prescriptions for anti-tuberculosis drugs may increase as well. Clinicians should be aware of the possibility of immediate hypersensitivity as well as delayed hypersensitivity to anti-tuberculosis drugs.
Angioedema*
;
Dizziness
;
Drug Hypersensitivity
;
Edema
;
Ethambutol
;
Exanthema
;
Female
;
Humans
;
Hypersensitivity, Delayed
;
Hypersensitivity, Immediate
;
Hypotension
;
Isoniazid
;
Middle Aged
;
Prescriptions
;
Prevalence
;
Pyrazinamide
;
Rifampin
;
Tuberculosis
;
Tuberculosis, Lymph Node
;
Tuberculosis, Pulmonary
;
Urticaria*
8.Prenatal Diagnosis of Bilateral Pulmonary Agenesis: a Case Report.
Kyung A LEE ; Jeong Yeon CHO ; Seung Mi LEE ; Jong Kwan JUN ; Jieun KANG ; Jeong Wook SEO
Korean Journal of Radiology 2010;11(1):119-122
We report a case of bilateral pulmonary agenesis (BPA), which was suspected during a prenatal US examination and diagnosed by fetal magnetic resonance imaging (MRI). BPA is an extremely rare congenital anomaly and, although many fetal structural defects can be detected with a high degree of confidence after introducing high-resolution US, the prenatal diagnosis of BPA remains problematic. Other thoracic abnormalities, such as a congenital diaphragmatic hernia, congenital cystic adenomatoid malformation, and pulmonary sequestration, should be excluded from the list of possible diagnoses before coming to the conclusion of BPA, because BPA is absolutely incompatible with extrauterine life, and an accurate internal diagnosis can prevent a futile intervention from being performed.
Abnormalities, Multiple
;
Female
;
Humans
;
Infant, Newborn
;
Lung/*abnormalities/ultrasonography
;
*Magnetic Resonance Imaging
;
Male
;
Pregnancy
;
*Prenatal Diagnosis
;
*Ultrasonography, Prenatal
9.Comparison of Supplemented Brucella Agar and Modified Clostridium difficile Agar for Antimicrobial Susceptibility Testing of Clostridium difficile.
Gye Hyeong KIM ; Jieun KIM ; Hyunjoo PAI ; Jung Oak KANG
Annals of Laboratory Medicine 2014;34(6):439-445
BACKGROUND: Antimicrobial susceptibility testing (AST) of Clostridium difficile is increasingly important because of the rise in resistant strains. The standard medium for the AST of C. difficile is supplemented Brucella agar (sBA), but we found that the growth of C. difficile on sBA was not optimal. Because active growth is critical for reliable AST, we developed a new, modified C. difficile (mCD) agar. C. difficile grew better on mCD agar than on sBA. METHODS: C. difficile isolates were collected from patients with healthcare-associated diarrhea. sBA medium was prepared according to the CLSI guidelines. Homemade mCD agar containing taurocholate, L-cysteine hydrochloride, and 7% horse blood was used. For 171 C. difficile isolates, we compared the agar dilution AST results from mCD agar with those from sBA. RESULTS: No significant differences were observed in the 50% minimal inhibitory concentration (MIC50) and 90% minimal inhibitory concentration (MIC90) of clindamycin (CLI), metronidazole (MTZ), moxifloxacin (MXF), piperacillin-tazobactam (PTZ), and rifaximin (RIX), but the values for vancomycin (VAN) were two-fold higher on mCD agar than on sBA. The MICs of CLI, MXF, and RIX were in 100% agreement within two-fold dilutions, but for MTZ, VAN, and PTZ, 13.7%, 0.6%, and 3.1% of the isolates, respectively, were outside the acceptable range. CONCLUSIONS: The MIC ranges, MIC50 and MIC90, were acceptable when AST was performed on mCD agar. Thus, mCD agar could be used as a substitute medium for the AST of C. difficile.
Anti-Infective Agents/*pharmacology
;
Clostridium Infections/microbiology
;
Clostridium difficile/*drug effects/isolation & purification
;
Diarrhea/*microbiology
;
Humans
;
Microbial Sensitivity Tests/*methods
10.Hospital Volume Threshold Associated with Higher Survival after Endovascular Recanalization Therapy for Acute Ischemic Stroke
Dong-Hyun SHIM ; Youngsoo KIM ; Jieun ROH ; Jongsoo KANG ; Kyung-Pil PARK ; Jae-Kwan CHA ; Seung Kug BAIK ; Yoon KIM
Journal of Stroke 2020;22(1):141-149
Background:
and Purpose Endovascular recanalization therapy (ERT) is becoming increasingly important in the management of acute ischemic stroke (AIS). However, the hospital volume threshold for optimal ERT remains unknown. We investigated the relationship between hospital volume of ERT and risk-adjusted patient outcomes.
Methods:
From the National Health Insurance claims data in Korea, 11,745 patients with AIS who underwent ERT from July 2011 to June 2016 in 111 hospitals were selected. We measured the hospital’s ERT volume and patient outcomes, including the 30-day mortality, readmission, and postprocedural intracranial hemorrhage (ICH) rates. For each outcome measure, we constructed risk-adjusted prediction models incorporating demographic variables, the modified Charlson comorbidity index, and the stroke severity index (SSI), and validated them. Risk-adjusted outcomes of AIS cases were compared across hospital quartiles to confirm the volume-outcome relationship (VOR) in ERT. Spline regression was performed to determine the volume threshold.
Results:
The mean AIS volume was 14.8 cases per hospital/year and the unadjusted means of mortality, readmission, and ICH rates were 11.6%, 4.6%, and 8.6%, respectively. The VOR was observed in the risk-adjusted 30-day mortality rate across all quartile groups, and in the ICH rate between the first and fourth quartiles (P<0.05). The volume threshold was 24 cases per year.
Conclusions
There was an association between hospital volume and outcomes, and the volume threshold in ERT was identified. Policies should be developed to ensure the implementation of the AIS volume threshold for hospitals performing ERT.